Pub Date : 2013-11-15DOI: 10.2174/1876526201305010049
Niki Mourouti, C. Papavagelis, M. Kontogianni, Petrini Plytzanopoulou, T. Vassilakou, N. Malamos, A. Linos, D. Panagiotakos
Background: Previous studies have suggested that individual cardiometabolic factors may be associated with an increased risk of breast cancer. Objective: To evaluate the association between individual cardiometabolic factors with breast cancer development. Design: A case - control study. Two-hundred-and-fifty consecutive, newly diagnosed breast cancer female patients (56±12 years) and 250, one-to-one age-matched with the patients, healthy volunteers (controls), were studied. A standardized, validated questionnaire assessing various socio-demographic, clinical, lifestyle and dietary characteristics, was applied through face-to-face interviews. Adherence to the Mediterranean diet was evaluated using the 11-components MedDietScore (theoretical range 0-55). A detailed medical history regarding the common co-morbidities (i.e., diabetes, hypertension, hypercholesterolemia) and their treatment was also recorded, while women were also catego- rized using the Body Mass Index (BMI) as an indicator of obesity. Results: Obesity (i.e., BMI>30 kg/m 2 ) was positively associated with the likelihood of having breast cancer. Conclusions: With the exception of obesity, none of the other tested cardiometabolic risk factors seemed to be a predisposing factor for breast cancer development.
{"title":"Cardiometabolic Factors and Breast Cancer: A Case-Control Study in Women","authors":"Niki Mourouti, C. Papavagelis, M. Kontogianni, Petrini Plytzanopoulou, T. Vassilakou, N. Malamos, A. Linos, D. Panagiotakos","doi":"10.2174/1876526201305010049","DOIUrl":"https://doi.org/10.2174/1876526201305010049","url":null,"abstract":"Background: Previous studies have suggested that individual cardiometabolic factors may be associated with an increased risk of breast cancer. Objective: To evaluate the association between individual cardiometabolic factors with breast cancer development. Design: A case - control study. Two-hundred-and-fifty consecutive, newly diagnosed breast cancer female patients (56±12 years) and 250, one-to-one age-matched with the patients, healthy volunteers (controls), were studied. A standardized, validated questionnaire assessing various socio-demographic, clinical, lifestyle and dietary characteristics, was applied through face-to-face interviews. Adherence to the Mediterranean diet was evaluated using the 11-components MedDietScore (theoretical range 0-55). A detailed medical history regarding the common co-morbidities (i.e., diabetes, hypertension, hypercholesterolemia) and their treatment was also recorded, while women were also catego- rized using the Body Mass Index (BMI) as an indicator of obesity. Results: Obesity (i.e., BMI>30 kg/m 2 ) was positively associated with the likelihood of having breast cancer. Conclusions: With the exception of obesity, none of the other tested cardiometabolic risk factors seemed to be a predisposing factor for breast cancer development.","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-15DOI: 10.2174/1876526201305010045
Andromachi Reklou, A. Kamparoudis, A. Mamopoulos, A. Lazaridis, P. Rakitzi, M. Grammatiki, M. Doumas, E. Gkaliagkousi, C. Spiridis, A. Karagiannis
Pheochromocytoma during pregnancy is rare and lethal to the mother and fetus. Its diagnosis is often missed during pregnancy and is usually made during labour or immediately postpartum with increased mortality rates for both the mother and fetus. Early diagnosis and timely, appropriate management reduce possible maternal and fetal complications. A case of pheochromocytoma recognized at early pregnancy is described.
{"title":"Management of Pheochromocytoma in Pregnancy: Case Report andReview of the Literature","authors":"Andromachi Reklou, A. Kamparoudis, A. Mamopoulos, A. Lazaridis, P. Rakitzi, M. Grammatiki, M. Doumas, E. Gkaliagkousi, C. Spiridis, A. Karagiannis","doi":"10.2174/1876526201305010045","DOIUrl":"https://doi.org/10.2174/1876526201305010045","url":null,"abstract":"Pheochromocytoma during pregnancy is rare and lethal to the mother and fetus. Its diagnosis is often missed during pregnancy and is usually made during labour or immediately postpartum with increased mortality rates for both the mother and fetus. Early diagnosis and timely, appropriate management reduce possible maternal and fetal complications. A case of pheochromocytoma recognized at early pregnancy is described.","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-15DOI: 10.2174/1876526201305010048
E. Georgousopoulou, G. Georgiopoulos, D. Panagiotakos
{"title":"LETTER TO THE EDITOR: Dietary Assessment and Cardiovascular Disease Risk Scores","authors":"E. Georgousopoulou, G. Georgiopoulos, D. Panagiotakos","doi":"10.2174/1876526201305010048","DOIUrl":"https://doi.org/10.2174/1876526201305010048","url":null,"abstract":"","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010023
K. Tziomalos, M. Doumas, V. Athyros
The concept of ideal cardiovascular (CV) health, with emphasis on the prevention of CV disease (CVD), was included by the American Heart Association (AHA) among its strategic goals for 2020 [1]. This concept was intended to focus mainly on the promotion of a healthy lifestyle and the adoption of a multifactorial intervention with nonpharmacological or pharmacological means, aiming at the prevention or the effective control of CVD risk factors [1]. Ideal CV health is defined as optimal levels of 3 CVD risk factors [blood pressure (BP), fasting plasma glucose and total cholesterol) and 4 behaviours [body mass index (BMI), smoking, physical activity and healthy diet] [1]. These 7 ideal CV metrics, called life's simple 7, are probably the best available markers of life-time CVD risk [2]. Recent studies have shown that the levels of ideal CV health in the United States to be very low at a community level [3-5] and to be associated with cardiac events [3], stroke [2] and total mortality [6]. A large study was conducted in 5,785 young adults (20-39 years old) from 5 international populations: the Minneapolis Childhood Cohort Study, the Princeton Follow-up Study, the Bogalusa Heart Study, the Cardiovascular Risk in Young Finns Study, and the Childhood Determinants of Adult Health (CDAH) Study; all members of the International Childhood Cardiovascular Cohort (i3C) Consortium [7]. Results of the study showed that ideal CV health, as defined by the AHA, was rare among young participants of the study. An amazingly low (only 1%) percentage of the participants had all 7 health metrics in the 5,785 young adults participating from all international cohorts [7]. Many of the participants had ideal glucose (73%), cholesterol (64%), and were non-smokers (64%); diet (7%) was the least common metric for participants from any of the cohorts [7]. The lowest prevalence of a clinical CVD risk factor from the life's 7 simple was BP; this was normal in only 52% of the
{"title":"EDITORIAL: No-Pharmacological Intervention: Pomegranate Juice for the Managementof Hypertension and the Improvement of Cardiovascular Health","authors":"K. Tziomalos, M. Doumas, V. Athyros","doi":"10.2174/1876526201305010023","DOIUrl":"https://doi.org/10.2174/1876526201305010023","url":null,"abstract":"The concept of ideal cardiovascular (CV) health, with emphasis on the prevention of CV disease (CVD), was included by the American Heart Association (AHA) among its strategic goals for 2020 [1]. This concept was intended to focus mainly on the promotion of a healthy lifestyle and the adoption of a multifactorial intervention with nonpharmacological or pharmacological means, aiming at the prevention or the effective control of CVD risk factors [1]. Ideal CV health is defined as optimal levels of 3 CVD risk factors [blood pressure (BP), fasting plasma glucose and total cholesterol) and 4 behaviours [body mass index (BMI), smoking, physical activity and healthy diet] [1]. These 7 ideal CV metrics, called life's simple 7, are probably the best available markers of life-time CVD risk [2]. Recent studies have shown that the levels of ideal CV health in the United States to be very low at a community level [3-5] and to be associated with cardiac events [3], stroke [2] and total mortality [6]. A large study was conducted in 5,785 young adults (20-39 years old) from 5 international populations: the Minneapolis Childhood Cohort Study, the Princeton Follow-up Study, the Bogalusa Heart Study, the Cardiovascular Risk in Young Finns Study, and the Childhood Determinants of Adult Health (CDAH) Study; all members of the International Childhood Cardiovascular Cohort (i3C) Consortium [7]. Results of the study showed that ideal CV health, as defined by the AHA, was rare among young participants of the study. An amazingly low (only 1%) percentage of the participants had all 7 health metrics in the 5,785 young adults participating from all international cohorts [7]. Many of the participants had ideal glucose (73%), cholesterol (64%), and were non-smokers (64%); diet (7%) was the least common metric for participants from any of the cohorts [7]. The lowest prevalence of a clinical CVD risk factor from the life's 7 simple was BP; this was normal in only 52% of the","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010032
M. Doumas, K. Tziomalos, V. Athyros
The results of the Dyslipidemia International Study (DYSIS) were reported yesterday in the European Society of Cardiology (ESC) congress held at Amsterdam, Netherlands [1]. DYSIS compared low density lipoprotein cholesterol (LDL-C) target achievement in two West European Countries, UK, with an incentive-driven reimbursement system and Germany, with a budget-restrictive healthcare system. Overall, 80% of UK patients achieved the LDL-C target of <100 mg/dL (mean levels 82 mg/dL), compared with just 42% of patients in Germany (mean levels 111 mg/dL), despite the higher use of ezetimibe in the German population than in the UK population (11 vs. 3%). Dyslipidemic patients in the UK were more likely to be treated with potent statins whereas German doctors were more concerned with insurance restrictions than UK physicians [1]. Thus, it seems that lipid targets are more likely to be achieved in clinical practice in pay-for-performance than in budget-restrictive systems, like in Germany [1]. The UK healthcare system makes physicians participate in a clinical audit, and these results are used to assess the quality of care provided. There are no specific quality-improvement strategies in Germany. Interestingly, the German reimbursement for atorvastatin changed in recent years, and many patients were subsequently switched to the less potent simvastatin [1]. A total of 85% of German patients were treated with simvastatin (average dose 27 mg/d) compared with just 66% of UK patients (average simvastatin dose 37 mg/d), while nearly 25% of UK patients were treated with atorvastatin (average dose 34 mg/d) vs. just
{"title":"LETTER TO THE EDITORPay-for-performance Versus a Budget-Restrictive System for the Managementof Dyslipidemia. Should this Approach also be Applied in Hypertension?","authors":"M. Doumas, K. Tziomalos, V. Athyros","doi":"10.2174/1876526201305010032","DOIUrl":"https://doi.org/10.2174/1876526201305010032","url":null,"abstract":"The results of the Dyslipidemia International Study (DYSIS) were reported yesterday in the European Society of Cardiology (ESC) congress held at Amsterdam, Netherlands [1]. DYSIS compared low density lipoprotein cholesterol (LDL-C) target achievement in two West European Countries, UK, with an incentive-driven reimbursement system and Germany, with a budget-restrictive healthcare system. Overall, 80% of UK patients achieved the LDL-C target of <100 mg/dL (mean levels 82 mg/dL), compared with just 42% of patients in Germany (mean levels 111 mg/dL), despite the higher use of ezetimibe in the German population than in the UK population (11 vs. 3%). Dyslipidemic patients in the UK were more likely to be treated with potent statins whereas German doctors were more concerned with insurance restrictions than UK physicians [1]. Thus, it seems that lipid targets are more likely to be achieved in clinical practice in pay-for-performance than in budget-restrictive systems, like in Germany [1]. The UK healthcare system makes physicians participate in a clinical audit, and these results are used to assess the quality of care provided. There are no specific quality-improvement strategies in Germany. Interestingly, the German reimbursement for atorvastatin changed in recent years, and many patients were subsequently switched to the less potent simvastatin [1]. A total of 85% of German patients were treated with simvastatin (average dose 27 mg/d) compared with just 66% of UK patients (average simvastatin dose 37 mg/d), while nearly 25% of UK patients were treated with atorvastatin (average dose 34 mg/d) vs. just","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010035
B. Nikolaidou, N. Katsiki, A. Lazaridis, Andromachi Reklou, M. Grammatiki, M. Doumas
We have read with great interest the study by Cicero and colleagues [1], reporting the long-term effects of lipidlowering nutraceuticals on Low Density Lipoprotein Cholesterol (LDL-C) levels and arterial stiffness. The impressive reduction of LDL-C combined with the excellent safety profile points towards further research in this field and calls for a wider use of nutraceuticals in everyday clinical practice. Furthermore, the beneficial effects of nutraceuticals in patients with chronic kidney disease (CKD) are of clinical importance, since this group of patients is highly susceptible to atherosclerosis and cardiovascular disease is their primary cause of death [2-4].
{"title":"LETTER TO THE EDITOR: The Effects of Nutraceuticals in Patients with or without Chronic Kidney Disease: Classification Matters","authors":"B. Nikolaidou, N. Katsiki, A. Lazaridis, Andromachi Reklou, M. Grammatiki, M. Doumas","doi":"10.2174/1876526201305010035","DOIUrl":"https://doi.org/10.2174/1876526201305010035","url":null,"abstract":"We have read with great interest the study by Cicero and colleagues [1], reporting the long-term effects of lipidlowering nutraceuticals on Low Density Lipoprotein Cholesterol (LDL-C) levels and arterial stiffness. The impressive reduction of LDL-C combined with the excellent safety profile points towards further research in this field and calls for a wider use of nutraceuticals in everyday clinical practice. Furthermore, the beneficial effects of nutraceuticals in patients with chronic kidney disease (CKD) are of clinical importance, since this group of patients is highly susceptible to atherosclerosis and cardiovascular disease is their primary cause of death [2-4].","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010041
K. Tziomalos, M. Doumas, V. Athyros
Price and availability of pomegranate juice (PJ) are indeed two major issues. The daily cost of PJ consumption is ranging from 0.5 to 1 $ per day, according to the dose used. PJ is available in almost all Western and several Asian countries. PJ is preserved in deep refrigeration and is readily available during the entire year. PJ circulates mainly in two forms: pure juice in 200 to 500 mL bottles (adulteration is practically impossible, because the color and the taste are unique) and in 1 L bottles, blended with purple grape juice without added sugar. The later contains resveratrol, a type of natural phenol and a phytoalexin, found in the skin of red grapes with definite antidiabetic effects and proposed but not proved yet anti-aging and anticancer effects. Resveratrol treatment has shown beneficial effects on glucose and lipid metabolism in some, but not all studies [2,3]. Study population, resveratrol source, and dose vary widely, potentially explaining inconsistency of findings among studies. Enhancement in endothelial function, systolic blood pressure, and markers of oxidative stress and inflammation in several studies have been reported [2,3].
{"title":"LETTER TO THE EDITOR: Pomegranate Juice is Useful for the Management of Hypertension and the Improvement of Cardiovascular Health","authors":"K. Tziomalos, M. Doumas, V. Athyros","doi":"10.2174/1876526201305010041","DOIUrl":"https://doi.org/10.2174/1876526201305010041","url":null,"abstract":"Price and availability of pomegranate juice (PJ) are indeed two major issues. The daily cost of PJ consumption is ranging from 0.5 to 1 $ per day, according to the dose used. PJ is available in almost all Western and several Asian countries. PJ is preserved in deep refrigeration and is readily available during the entire year. PJ circulates mainly in two forms: pure juice in 200 to 500 mL bottles (adulteration is practically impossible, because the color and the taste are unique) and in 1 L bottles, blended with purple grape juice without added sugar. The later contains resveratrol, a type of natural phenol and a phytoalexin, found in the skin of red grapes with definite antidiabetic effects and proposed but not proved yet anti-aging and anticancer effects. Resveratrol treatment has shown beneficial effects on glucose and lipid metabolism in some, but not all studies [2,3]. Study population, resveratrol source, and dose vary widely, potentially explaining inconsistency of findings among studies. Enhancement in endothelial function, systolic blood pressure, and markers of oxidative stress and inflammation in several studies have been reported [2,3].","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010040
F. Barkas, E. Liberopoulos
[1] Tziomalos K, Doumas M, Athyros V. No-pharmacological intervention: Pomegranate juice for the management of hypertension and the improvement of cardiovascular health. Open Hypertens J 2013, Current Issue. [2] Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical Evaluation of Blood Pressure Lowering, Endothelial Function Improving, Hypolipidemic and Anti-Inflammatory Effects of Pomegranate Juice in Hypertensive Subjects. Phytotherapy research : PTR 2013. [3] Davidson MH, Maki KC, Dicklin MR, et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J cardiol 2009; 104(7): 936-42. [4] Muraki I, Imamura F, Manson JE, et al. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ 2013; 347: f5001. [5] The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330(15): 1029-35. [6] Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 23-33. [7] Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368(14): 1279-90. [8] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-219.
{"title":"LETTER TO THE EDITORIs Pomegranate Juice Readily Available and Useful for the Management ofHypertension and the Improvement of Cardiovascular Health","authors":"F. Barkas, E. Liberopoulos","doi":"10.2174/1876526201305010040","DOIUrl":"https://doi.org/10.2174/1876526201305010040","url":null,"abstract":"[1] Tziomalos K, Doumas M, Athyros V. No-pharmacological intervention: Pomegranate juice for the management of hypertension and the improvement of cardiovascular health. Open Hypertens J 2013, Current Issue. [2] Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M. Clinical Evaluation of Blood Pressure Lowering, Endothelial Function Improving, Hypolipidemic and Anti-Inflammatory Effects of Pomegranate Juice in Hypertensive Subjects. Phytotherapy research : PTR 2013. [3] Davidson MH, Maki KC, Dicklin MR, et al. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J cardiol 2009; 104(7): 936-42. [4] Muraki I, Imamura F, Manson JE, et al. Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ 2013; 347: f5001. [5] The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330(15): 1029-35. [6] Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 highrisk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 23-33. [7] Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368(14): 1279-90. [8] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-219.","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010043
E. Ganotakis, A. Papagianni, V. Athyros
A few days ago (Sept 12, 2013) the results of a large prospective study that included 1,117 healthy children who were followed up for 27 years were presented in the American Heart Association (AHA) High Blood Pressure Research Scientific Sessions in New Orleans [1]. The aim was to record the development of obesity in childhood and to investigate the incidence of arterial hypertension (HTN) in adults that were obese or overweight children [1]. The original cohort was established in 1986, and consisted of 1,117 healthy children (47% male), recruited from schools in Indianapolis, Indiana, USA (mean age 12 years). During follow-up, blood pressure (BP), height, and weight were measured twice a year. Body mass index (BMI) was calculated from height and weight; weight status was determined by age and sexadjusted BMI percentile values (BMI %). Subjects were classified as normal weight, overweight (BMI% 85% and < 95%), or obese (BMI% 95%) of BMI distribution of the entire cohort [1]. The above revealed that 765 (68%) had normal weight, 176 (16%) were overweight, and 176 (16%) were obese [1]. The rate of adult HTN was higher for those classified as overweight or obese as children (14% and 26% respectively, p = <0.0001). Children classified as overweight or obese had double and quadruple the risk of having HTN in adulthood, respectively, as compared to normal weight children [odds ratio (OR) = 2.2; 95% confidence interval (CI) = 1.3 to 3.6, OR = 4.4; 95% CI = 2.8 to 6.9, respectively] [1]. It has also been shown that children who had one or more high BP readings are 3 times more likely to develop HTN as adults. Using the same pool of Indianapolis kids, researchers found that the rate of high BP during adulthood was 8.6% for children who didn't have a high BP reading when they were young. That rate jumped to 18% for adults who had at least 1 high reading as a kid, and 35% for adults who had 2 or more high readings as children [1]. This study highlights the need for pediatricians to regularly check BP
{"title":"CONGRESS COVERAGE: Obese Children have a Quadrupled Risk of Becoming Hypertensive Adults in Comparison to Children with Normal Weight","authors":"E. Ganotakis, A. Papagianni, V. Athyros","doi":"10.2174/1876526201305010043","DOIUrl":"https://doi.org/10.2174/1876526201305010043","url":null,"abstract":"A few days ago (Sept 12, 2013) the results of a large prospective study that included 1,117 healthy children who were followed up for 27 years were presented in the American Heart Association (AHA) High Blood Pressure Research Scientific Sessions in New Orleans [1]. The aim was to record the development of obesity in childhood and to investigate the incidence of arterial hypertension (HTN) in adults that were obese or overweight children [1]. The original cohort was established in 1986, and consisted of 1,117 healthy children (47% male), recruited from schools in Indianapolis, Indiana, USA (mean age 12 years). During follow-up, blood pressure (BP), height, and weight were measured twice a year. Body mass index (BMI) was calculated from height and weight; weight status was determined by age and sexadjusted BMI percentile values (BMI %). Subjects were classified as normal weight, overweight (BMI% 85% and < 95%), or obese (BMI% 95%) of BMI distribution of the entire cohort [1]. The above revealed that 765 (68%) had normal weight, 176 (16%) were overweight, and 176 (16%) were obese [1]. The rate of adult HTN was higher for those classified as overweight or obese as children (14% and 26% respectively, p = <0.0001). Children classified as overweight or obese had double and quadruple the risk of having HTN in adulthood, respectively, as compared to normal weight children [odds ratio (OR) = 2.2; 95% confidence interval (CI) = 1.3 to 3.6, OR = 4.4; 95% CI = 2.8 to 6.9, respectively] [1]. It has also been shown that children who had one or more high BP readings are 3 times more likely to develop HTN as adults. Using the same pool of Indianapolis kids, researchers found that the rate of high BP during adulthood was 8.6% for children who didn't have a high BP reading when they were young. That rate jumped to 18% for adults who had at least 1 high reading as a kid, and 35% for adults who had 2 or more high readings as children [1]. This study highlights the need for pediatricians to regularly check BP","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-14DOI: 10.2174/1876526201305010027
V. Notara, D. Panagiotakos
{"title":"LETTER TO THE EDITOR: Pomegranate Juice Intake and Cardiovascular Health","authors":"V. Notara, D. Panagiotakos","doi":"10.2174/1876526201305010027","DOIUrl":"https://doi.org/10.2174/1876526201305010027","url":null,"abstract":"","PeriodicalId":38918,"journal":{"name":"Open Hypertension Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68145920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：